Qing Zhang1, Mintallah Haider2, Najla H Al Ali2, Jeffrey E Lancet2, Pearlie K Epling-Burnette3, Alan F List2, Eric Padron4, Rami S Komrokji5. 1. Cancer Biology and Molecular Medicine, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. 2. Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. 3. Immunology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. 4. Cancer Biology and Molecular Medicine, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. 5. Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. Electronic address: rami.komrokji@moffitt.org.
Abstract
BACKGROUND: Immunosuppressive therapy (IST) yields durable hematologic improvement (HI) in a subset of patients with lower-risk myelodysplastic syndrome (MDS). Age, human leukocyte antigen (HLA)-DR15 positivity, and duration of transfusion dependence are putative clinical variables predictive for response. We investigated the effect of somatic gene mutations on response to IST in lower-risk MDS. PATIENTS AND METHODS: Forty of 66 patients who received antithymocyte globulin with or without cyclosporine A identified at the Moffitt Cancer Center were molecularly profiled using a 49-gene myeloid panel. All patients profiled received antithymocyte globulin, and cyclosporine A was provided to 60% of patients. RESULTS: The overall frequency of HI was 42%. Presence of a large granular lymphocytic clone, hypocellular bone marrow, HLA-DR15 positivity, trisomy 8, and age had no influence on response to IST. Among 40 patients evaluated by next-generation sequencing, the presence of an SF3B1 mutation (MT) was significantly associated with IST nonresponse (1 of 9 SF3B1 MT, 11% vs. 21 of 31 wild type, 68%; P = .002). All patients with SF3B1 MT had ring sideroblasts > 15% (RS) by morphology; the corresponding HI rate was 20% among patients with RS versus 50% for those without RS (P = .09). CONCLUSION: These findings support the clinical implementation of genomics in MDS. The presence of an SF3B1 mutation adversely influences response to IST and should be incorporated into treatment decisions upon validation of these findings.
BACKGROUND: Immunosuppressive therapy (IST) yields durable hematologic improvement (HI) in a subset of patients with lower-risk myelodysplastic syndrome (MDS). Age, human leukocyte antigen (HLA)-DR15 positivity, and duration of transfusion dependence are putative clinical variables predictive for response. We investigated the effect of somatic gene mutations on response to IST in lower-risk MDS. PATIENTS AND METHODS: Forty of 66 patients who received antithymocyte globulin with or without cyclosporine A identified at the Moffitt Cancer Center were molecularly profiled using a 49-gene myeloid panel. All patients profiled received antithymocyte globulin, and cyclosporine A was provided to 60% of patients. RESULTS: The overall frequency of HI was 42%. Presence of a large granular lymphocytic clone, hypocellular bone marrow, HLA-DR15 positivity, trisomy 8, and age had no influence on response to IST. Among 40 patients evaluated by next-generation sequencing, the presence of an SF3B1 mutation (MT) was significantly associated with IST nonresponse (1 of 9 SF3B1 MT, 11% vs. 21 of 31 wild type, 68%; P = .002). All patients with SF3B1 MT had ring sideroblasts > 15% (RS) by morphology; the corresponding HI rate was 20% among patients with RS versus 50% for those without RS (P = .09). CONCLUSION: These findings support the clinical implementation of genomics in MDS. The presence of an SF3B1 mutation adversely influences response to IST and should be incorporated into treatment decisions upon validation of these findings.
Authors: Bart L Scott; Aravind Ramakrishnan; Mark Fosdal; Barry Storer; Pamela Becker; Steve Petersdorf; H Joachim Deeg Journal: Br J Haematol Date: 2010-03-16 Impact factor: 6.998
Authors: Phillip Scheinberg; Olga Nunez; Barbara Weinstein; Priscila Scheinberg; Angélique Biancotto; Colin O Wu; Neal S Young Journal: N Engl J Med Date: 2011-08-04 Impact factor: 91.245
Authors: Elaine M Sloand; Matthew J Olnes; Aarthie Shenoy; Barbara Weinstein; Carol Boss; Kelsey Loeliger; Colin O Wu; Kenneth More; A John Barrett; Phillip Scheinberg; Neal S Young Journal: J Clin Oncol Date: 2010-11-01 Impact factor: 44.544
Authors: Rami S Komrokji; Adam W Mailloux; Dung-Tsa Chen; Mikkael A Sekeres; Ronald Paquette; William J Fulp; Chiharu Sugimori; Jennifer Paleveda-Pena; Jaroslaw P Maciejewski; Alan F List; Pearlie K Epling-Burnette Journal: Haematologica Date: 2014-01-31 Impact factor: 9.941
Authors: Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian Journal: Blood Date: 2006-04-11 Impact factor: 22.113
Authors: Jeffrey J Molldrem; Eric Leifer; Erkut Bahceci; Yogen Saunthararajah; Mary Rivera; Cynthia Dunbar; Johnson Liu; Riotoro Nakamura; Neal S Young; A John Barrett Journal: Ann Intern Med Date: 2002-08-06 Impact factor: 25.391